Skip nav

Updated NICE quality standard recommends Oncotype DX® in early-stage breast cancer

Media: Hazel Davis

• Multi-gene test developed by Genomic Health predicts likelihood of chemotherapy benefit and risk of disease recurrence

• Latest quality standard reveals areas for improvement in breast cancer treatment

[London, 20 June, 2016] Genomic Health UK announced that the National Institute for Health and Care Excellence (NICE) has published its latest quality standard, recommending the use of the Oncotype DX test in eligible patients with early-stage breast cancer.

The new standard states that people with oestrogen receptor-positive (ER-positive), human epidermal growth factor receptor 2-negative (HER2-negative) and lymph node-negative early breast cancer...

Read full release